Pharma Archives - Page 5 of 5

Speaker Interview With Gavin Reynolds For 4TH Annual MarketsandMarkets Epigenetics Congress

July 29, 2019 MarketsandMarkets Conferences

London, UK July 29, 2019 – MarketsandMarkets recently interviewed Gavin Reynolds, Professor Emeritus, Queen’s University Belfast, UK regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Gavin Reynolds is Honorary Professor at Sheffield Hallam University and Professor Emeritus, previously Chair of Neuroscience, at Queen’s University Belfast. His main research interests lie in two directions: the neurotransmitter pathology of schizophrenia, and the mechanisms underlying the beneficial and adverse effects of antipsychotics and other psychoactive drugs, with a recent focus on pharmacogenetic and…

Speaker Interview with Lorenzo Pasquali for 4th Annual MarketsandMarkets Epigenetics Congress

July 23, 2019July 23, 2019 MarketsandMarkets Conferences

London, UK July 23, 2019 – MarketsandMarkets recently interviewed Lorenzo Pasquali, Group Leader, Endocrine Regulatory Genomics Laboratory IGTP, Spain regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Dr. Lorenzo Pasquali is Group Leader of the Endocrine Regulatory Genomics laboratory at IGTP, Barcelona, Spain . His studies helped to map the epigenetic landscape of the insulin producing pancreatic islet cells resulting in milestone publications that opened the path to understand genomic regulation of the islets of Langerhans and shed…

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

July 19, 2019July 19, 2019 MarketsandMarkets Conferences

Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). A collaboration contract was signed by Catalent and AveXis to ensure long term strategic agreement but has not been disclosed yet. AveXis will use the dedicated production space within Paragon’s Harmans, MD, facility, a 151,000-square-foot old warehouse that Paragon changed into a contract developing and a manufacturing site which opened in April. Andy Stober,…

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

July 19, 2019July 19, 2019 MarketsandMarkets Conferences

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab plans to combine with its duo body platform technology to produce new bispecific antibodies for fighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this CD47 stating that “CD47 has shown…

Microba Partners with Korean Company Macrogen to Develop Global Microbiome Service Offering

July 9, 2019 MarketsandMarkets Conferences

Australian biotech giant Microba has made an alliance with Macrogen to develop microbiome research services for the offshore market. An MOU has got signed at the Macrogen Headquarters in Seoul on 14 March 2019 defining all the partnership terms and condition. Through this MOU, Macrogen and Microba will establish a close cooperation system. With this partnership, they will try to penetrate into the microbiome market of Korea and other nations Macrogen is a significant Korean company which has a market capitalization of 350m USD and annual revenues touching 100m USD….

The Bispecific and Complex mAbs Driving Process Development Innovation, Roche

July 4, 2019July 4, 2019 MarketsandMarkets Conferences

According to a statement by the VP of Roche technical development bioprocessing, Wolfgang Kuhne said that the older processes used to produce monoclonal antibodies like Herceptin and Avastin are not sufficient to produce complex and advanced pharmaceuticals. A bioprocess international European summit was held in Vienna, Austria during which delegates were told that making candidates like ACE910 – a bispecific antibody granted breakthrough designation for Haemophilia last September – had required a considerable process development effort. In his statement, he clarified by saying “There are no more classical standard approaches…

Improved version in CAR T-cell therapy seems to eliminate its serious side effects

May 30, 2019June 17, 2019 MarketsandMarkets Conferences

A USC study shows an improved version of CAR T-cell therapy seems to eliminate its serious side effects, which will make the treatment safer and potentially available in outpatient settings. Si – Yi Chen of the USC Norris Comprehensive Cancer Center, professor in the Department of Molecular Microbiology and Immunology at the Keck School of Medicine of USC, and senior author of the study said, “This is a major improvement”. He further added “We’ve made a new CAR molecule that’s just as efficient at killing cancer cells, but it works…

Interview with Ester Lovšin Barle – Speaker at 3rd Annual MarketsandMarkets High Potent Medicines Conference

April 2, 2019 MarketsandMarkets Conferences

MarketsandMarkets recently interviewed Ester Lovsin Barle, Corporate Toxicologist, Lonza regarding 3rd Annual MarketsandMarkets High Potent Medicines Conference taking place on 28th – 29th May 2019 in Milan, Italy. When asked about recent advances in the high potent medicines area and current challenges, and this is what she had to say. 1.What are the recent advances in the high potent medicines area and current challenges that need immediate attention? A – It is acknowledged that the hazards, as qualitative aspects are much easier to assess, communicate and perceive by the general…

Current Trends in Biomarker Research and Development

December 11, 2018August 27, 2019 cncadmin

It is rightly said ‘Prevention is better than cure’, it is wise to stop something happening or detecting early and that’s what biomarkers do, indicating the risk of particular disease for betterment. The biochemical characteristics measured that determines the particular physiological condition of a human is called as biomarkers and this has been a great help for the healthcare industry for investigation and making of laboratory medicines and drugs to manage chronic diseases and disorders. It’s a great advancement in disease management and improvement in patient’s outcome. The buzzword biomarker has…

CRISPR: An Emerging Technology for Genome Editing

December 10, 2018December 13, 2018 cncadmin

CRISPR is an abbreviation of Clustered Regularly Interspaced Short Palindromic Repeats. In simpler words, it is a family of DNA sequences in bacteria and other microorganisms. These CRISPR sequences are a crucial component of the immune systems of such organisms, playing a vital role in the bacterial defense mechanism in comb8ination with a protein (Cas9) to modify the genes within the organisms. CRISPR falls under the most specific and commonly used gene editing techniques wherein major investment is taking place in the biotechnology industry. What Is CRISPR? CRISPR is an…